

CITATION REPORT

List of articles citing

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-?

DOI: [10.1038/nature11060](https://doi.org/10.1038/nature11060)

Nature, 2012, 485, 651-5.

Source: <https://exaly.com/paper-pdf/54313949/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
341	The pyroglutamylated seed. 2012 , 13, 363-363		
340	The role of tau in neurodegenerative diseases and its potential as a therapeutic target. 2012 , 2012, 796024		44
339	Intraneuronal β amyloid and its interactions with proteins and subcellular organelles. 2012 , 33, 3608-16		20
338	Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. 2012 , 43, 694-8		67
337	Copper coordination to native N-terminally modified versus full-length amyloid- β second-sphere effects determine the species present at physiological pH. 2012 , 51, 12988-3000		34
336	Transmissible proteins: expanding the prion heresy. 2012 , 149, 968-77		169
335	Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research. 2012 , 4, 14		12
334	Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration. <i>Translational Neurodegeneration</i> , 2012 , 1, 24	10.3	41
333	Lösen modifizierte Amyloid-beta-Peptide die Alzheimer-Demenz aus?. 2012 , 14, 36-36		
332	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. 2012 , 2, 700		305
331	Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. 2012 , 7, e47261		59
330	Alzheimer's toxic chain reaction. 2012 , 11, 518-518		
329	The neurodegeneration in Alzheimer disease and the prion protein. 2013 , 7, 60-5		12
328	Structures of oligomers of a peptide from β amyloid. <i>Journal of the American Chemical Society</i> , 2013 , 135, 12460-7	16.4	46
327	Circadian clocks and neurodegenerative diseases: time to aggregate?. 2013 , 23, 880-7		67
326	The therapeutics of Alzheimer's disease: where we stand and where we are heading. 2013 , 74, 328-36		91
325	A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues. 2013 , 44, 1205-14		12

324	Molecular nexopathies: a new paradigm of neurodegenerative disease. 2013 , 36, 561-9		160
323	Recent progress in prion and prion-like protein aggregation. 2013 , 45, 520-6		5
322	Handedness and language learning disability differentially distribute in progressive aphasia variants. 2013 , 136, 3461-73		100
321	Glutamyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. 2013 , 14, 108		17
320	Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer's disease. 2013 , 37, 297-308		14
319	Slow excitotoxicity in Alzheimer's disease. 2013 , 35, 643-68		69
318	Rapid cytotoxicity screening platform for amyloid inhibitors using a membrane-potential sensitive fluorescent probe. 2013 , 85, 185-92		11
317	Pyroglutamate-3 amyloid- β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. 2013 , 183, 369-81		84
316	Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid β protein. 2013 , 425, 2260-75		42
315	From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. <i>Journal of Neurochemistry</i> , 2013 , 126, 183-90	6	35
314	Amyloid- β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. 2013 , 126, 1278-86		111
313	Alzheimer disease: a tale of two prions. 2013 , 7, 14-9		85
312	Tau pathology and neurodegeneration. 2013 , 12, 609-22		698
311	Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. 2013 , 74, 367-74		78
310	NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. 2013 , 4, e608		97
309	Peripherally applied synthetic peptide isoAsp7-A β (1-42) triggers cerebral β amyloidosis. 2013 , 24, 370-6		50
308	Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia (review). 2013 , 31, 3-10		32
307	Structure-activity relationship of human glutamyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. 2013 , 21, 3821-30		25

306	Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid- β in TgCRND8 mice. 2013 , 4, 613-23	19
305	Assessing the causes and consequences of co-polymerization in amyloid formation. 2013 , 7, 359-68	37
304	Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. 2013 , 3, 1302	78
303	Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. 2013 , 2013, 583498	18
302	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. 2013 , 3, 1472	70
301	Expanding the repertoire of amyloid polymorphs by co-polymerization of related protein precursors. 2013 , 288, 7327-37	32
300	Context dependence of protein misfolding and structural strains in neurodegenerative diseases. 2013 , 100, 722-30	12
299	Emerging Therapeutic Strategies in Alzheimer's Disease. 2013 ,	1
298	Alzheimer's disease and prion protein. 2013 , 2, 35-44	12
297	Hairpin-mediated formation of structurally distinct multimers of neurotoxic prion peptides. 2014 , 9, e87354	16
296	Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo. 2014 , 9, e94812	20
295	Prions and prion-like pathogens in neurodegenerative disorders. 2014 , 3, 149-63	13
294	The triple power of D β protein intrinsic disorder in degenerative diseases. 2014 , 19, 181-258	62
293	Parkin overexpression ameliorates hippocampal long-term potentiation and β amyloid load in an Alzheimer's disease mouse model. 2014 , 23, 1056-72	50
292	Towards Small Molecules as Therapies for Alzheimer's Disease and Other Neurodegenerative Disorders. 2014 , 199-290	1
291	A sensitive oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. 2014 , 34, 2884-97	103
290	Spreading of amyloid- β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. 2014 , 65, 82-92	100
289	β amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. 2014 , 35, 449-59	35

288	Emerging therapeutics for Alzheimer's disease. 2014 , 54, 381-405		63
287	Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. 2014 , 71, 4803-13		33
286	Monoclonal antibodies against A β 2 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. 2014 , 289, 32131-32143		77
285	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. 2014 , 1842, 2457-67		10
284	Pyroglutamylated amyloid- β peptide reverses cross β sheets by a prion-like mechanism. 2014 , 118, 5637-43		20
283	A fibril-like assembly of oligomers of a peptide derived from β amyloid. <i>Journal of the American Chemical Society</i> , 2014 , 136, 12682-90	16.4	30
282	Activity and architecture of pyroglutamate-modified amyloid- β (A β E3-42) pores. 2014 , 118, 7335-44		28
281	Amyloid-beta (A β) induced paralysis in <i>Caenorhabditis elegans</i> is inhibited by the polyphenol quercetin through activation of protein degradation pathways. 2014 , 58, 1931-40		85
280	Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. 2014 , 71, 53-61		57
279	Focusing the amyloid cascade hypothesis on N-truncated A β peptides as drug targets against Alzheimer's disease. 2014 , 127, 787-801		99
278	Pyroglutamylated amyloid- β s associated with hyperphosphorylated tau and severity of Alzheimer's disease. 2014 , 128, 67-79		48
277	Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. <i>Translational Neurodegeneration</i> , 2014 , 3, 10	10.3	28
276	Amyloid- β and tau: the trigger and bullet in Alzheimer disease pathogenesis. 2014 , 71, 505-8		919
275	Role of the fast kinetics of pyroglutamate-modified amyloid- β oligomers in membrane binding and membrane permeability. 2014 , 53, 4704-14		25
274	Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy. 2014 , 82, 478-80		10
273	Seizure resistance without parkinsonism in aged mice after tau reduction. 2014 , 35, 2617-2624		53
272	A role for tau at the synapse in Alzheimer's disease pathogenesis. 2014 , 76 Pt A, 1-8		124
271	Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death. 2014 , 63, 62-73		16

270	Structural and functional analyses of a glutaminyl cyclase from <i>Ixodes scapularis</i> reveal metal-independent catalysis and inhibitor binding. 2014 , 70, 789-801		6
269	Sources of extracellular tau and its signaling. 2014 , 40 Suppl 1, S7-S15		22
268	Polymorphism of oligomers of a peptide from β amyloid. <i>Journal of the American Chemical Society</i> , 2014 , 136, 5432-42	16.4	23
267	Mouse strain and brain region-specific expression of the glutaminyl cyclases QC and isoQC. 2014 , 36, 64-73		13
266	Amyloid-beta (A β -42)-induced paralysis in <i>Caenorhabditis elegans</i> is reduced by restricted cholesterol supply. 2014 , 576, 93-6		12
265	Brain pyroglutamate amyloid- β s produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. 2014 , 41, 129-49		50
264	Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid- β load and cognitive decline in Alzheimer's disease. 2014 , 39, 385-400		66
263	Pyroglutamate-amyloid- β and glutaminyl cyclase are colocalized with amyloid- β in secretory vesicles and undergo activity-dependent, regulated secretion. 2014 , 14, 85-97		7
262	Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology. 2016 , 50, 111-26		15
261	A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a γ glutaminyl cyclase inhibitor, in healthy subjects. 2015 , 1, 182-195		31
260	Pyroglutamyl-N-terminal prion protein fragments in sheep brain following the development of transmissible spongiform encephalopathies. 2015 , 2, 7		4
259	Neuron Loss and Behavioral Deficits in the TBA42 Mouse Model Expressing N-Truncated Pyroglutamate Amyloid- β -42. 2015 , 45, 471-82		12
258	The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2015 , 133, 1-13	6	60
257	Detection and Quantification of β Amyloid, Pyroglutamyl A β and Tau in Aged Canines. 2015 , 74, 912-23		41
256	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A β pathology and modulates A β oligomerization. 2015 , 82, 552-560		36
255	Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties. 2015 , 80, 1800-19		24
254	Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides. 2015 , 17, 32149-60		13
253	Inhibition of protein aggregation and amyloid formation by small molecules. 2015 , 30, 50-56		210

252	A β induces PUMA activation: a new mechanism for A β -mediated neuronal apoptosis. 2015 , 36, 789-800	19
251	Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. 2015 , 129, 183-206	359
250	Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease. 2015 , 129, 565-83	27
249	A β stretching-and-packing β -cross-seeding mechanism can trigger tau protein aggregation. 2015 , 6, 3276-3282	34
248	Ginsenoside Rd attenuates A β 5-35-induced oxidative stress and apoptosis in primary cultured hippocampal neurons. 2015 , 239, 12-8	35
247	Extracellular vesicles in Alzheimer's disease: friends or foes? Focus on a β -vesicle interaction. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 4800-13	6.3 61
246	Insights into the consequences of co-polymerisation in the early stages of IAPP and A β peptide assembly from mass spectrometry. 2015 , 140, 6990-9	34
245	Animal models for prion-like diseases. 2015 , 207, 5-24	10
244	Tau reduction prevents A β -induced axonal transport deficits by blocking activation of GSK3 β . 2015 , 209, 419-33	99
243	The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro. 2015 , 6, 60	12
242	Synthesis and evaluation of [¹⁴ C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation. 2015 , 6, 1065-1068	10
241	Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. 2015 , 35, 4857-68	99
240	Amyloid β protein and Alzheimer's disease: When computer simulations complement experimental studies. 2015 , 115, 3518-63	426
239	An anti-pyroglutamate-3 A β vaccine reduces plaques and improves cognition in APP ^{Swe} /PS1 ^{E9} mice. 2015 , 36, 3187-3199	36
238	Amyloid beta modulation of neuronal network activity in vitro. 2015 , 1629, 1-9	25
237	Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias. 2015 , 15, 1245-8	7
236	Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease. 2015 , 5, 96074-96079	59
235	Prion Diseases. 2015 , 356-374	3

234	Astrocytes and microglia but not neurons preferentially generate N-terminally truncated A β peptides. 2015 , 73, 24-35	36
233	Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease. 2015 , 41, 631-45	19
232	Oleuropein aglycone protects against pyroglutamylated-3 amyloid- β toxicity: biochemical, epigenetic and functional correlates. 2015 , 36, 648-63	76
231	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model. <i>Current Alzheimer Research</i> , 2016 , 13, 663-677	3 9
230	A modification-specific peptide-based immunization approach using CRM197 carrier protein. 2017 , 22, 841-849	5
229	Amyloid-Beta Induced Changes in Vesicular Transport of BDNF in Hippocampal Neurons. 2016 , 2016, 4145708	21
228	Tau: The Center of a Signaling Nexus in Alzheimer's Disease. 2016 , 10, 31	68
227	Verstärkte Fibrillen-Fragmentierung N-terminal verkürzter, Pyroglutamat-modifizierter A β Peptide. 2016 , 128, 5165-5168	5
226	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. 2016 , 31, 771-81	66
225	Immunotherapy targeting pyroglutamate-3 A β prospects and challenges. 2016 , 11, 48	28
224	Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified A β Peptides. 2016 , 55, 5081-4	25
223	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. 2016 , 6, 38187	76
222	Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function. 2016 , 54, 3-29	17
221	Tau: From research to clinical development. 2016 , 12, 1033-1039	87
220	Phosphorylation of the amyloid β peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. 2016 , 131, 525-37	65
219	Molecular architecture of A β fibrils grown in cerebrospinal fluid solution and in a cell culture model of A β plaque formation. 2016 , 23, 76-85	1
218	Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid- β Induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. 2016 , 291, 1719-1734	24
217	Amyloid- β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease. 2016 , 26, 269-275	23

216	A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. 2016 , 291, 19235-44	113
215	The amyloid hypothesis of Alzheimer's disease at 25 years. 2016 , 8, 595-608	2876
214	A critical concentration of N-terminal pyroglutamylated amyloid beta drives the misfolding of Ab1-42 into more toxic aggregates. 2016 , 79, 261-270	36
213	Immunotherapy Against N-Truncated Amyloid- β Oligomers. 2016 , 37-50	3
212	Tau and tauopathies. 2016 , 126, 238-292	292
211	Lecture 11. 2016 , 151-163	0
210	Fibrils of Truncated Pyroglutamyl-Modified A β Peptide Exhibit a Similar Structure as Wildtype Mature A β Fibrils. 2016 , 6, 33531	9
209	Soluble pre-fibrillar tau and β amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. 2016 , 132, 875-895	66
208	pGluA β increases accumulation of A β in vivo and exacerbates its toxicity. 2016 , 4, 109	23
207	Anti-Amyloid- β Immunotherapy for Alzheimer's Disease. 2016 , 193-226	6
206	Small molecule NPT-440-1 inhibits ionic flux through A β pores: Implications for Alzheimer's disease therapeutics. 2016 , 12, 2331-2340	1
205	Comparative pathobiology of β amyloid and the unique susceptibility of humans to Alzheimer's disease. 2016 , 44, 185-196	31
204	Molecular and genetic inflammation networks in major human diseases. 2016 , 12, 2318-41	39
203	Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method. 2016 , 6, 3586-3591	52
202	Amyloid- β Peptide A β PE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. 2016 , 291, 6134-45	63
201	Clasmatodendrosis and β amyloidosis in aging hippocampus. 2016 , 30, 1480-91	11
200	Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloid. 2016 , 85, 130-143	15
199	Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening. 2017 , 21, 175-186	10

198	Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins. 2017 , 329, 145-185		14
197	Phosphorylation at Ser as an Intrinsic Regulatory Switch to Regulate the Morphologies and Structures of Alzheimer's 40-residue A β Fibrils. 2017 , 292, 2611-2623		19
196	Discovery of Potent Human Glutamyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design. 2017 , 60, 2573-2590		23
195	Evidence of Molecular Interactions of A β -42 with N-Terminal Truncated Beta Amyloids by NMR. 2017 , 8, 759-765		8
194	Posttranslational modification impact on the mechanism by which amyloid- β induces synaptic dysfunction. 2017 , 18, 962-981		30
193	Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction. 2017 , 58, 803-820		34
192	Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers. 2017 , 8, 5030-5040		31
191	Dysregulated Metabolism of the Amyloid- β Protein and Therapeutic Approaches in Alzheimer Disease. 2017 , 118, 4183-4190		20
190	Tau association with synaptic vesicles causes presynaptic dysfunction. <i>Nature Communications</i> , 2017 , 8, 15295	17.4	168
189	Glutamyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy. 2017 , 362, 119-130		31
188	Structural and functional analyses of pyroglutamate-amyloid- β -specific antibodies as a basis for Alzheimer immunotherapy. 2017 , 292, 12713-12724		19
187	Immunization of Tg-APP ^{swe} /PSEN1 ^{dE9} mice with A β -10-KLH vaccine prevents synaptic deficits of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017 , 332, 64-70	3.4	2
186	Purification of recombinant A β (1-42) and pGlu-A β (B-42) using preparative SDS-PAGE. 2017 , 38, 2042-2049		3
185	Stabilizing the monomeric amyloid- β peptide by tyrocidine A prevents and reverses amyloidogenesis without the accumulation of oligomers. 2017 , 53, 3886-3889		15
184	Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure. 2017 , 284, 1355-1369		8
183	Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice. 2017 , 8, 454-459		7
182	Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid- β Peptide. 2017 , 292, 3172-3185		76
181	Pyroglutamate-amyloid- β peptide expression in <i>Drosophila</i> leads to caspase-dependent and endoplasmic reticulum stress-related progressive neurodegeneration. 2017 , 26, 4642-4656		3

180	Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?. 2017 , 9, 1979-1981	4
179	Exploring the Aggregation Mechanism of Intrinsically Disordered Tau Protein. 2017 , 51-71	
178	Human TAU overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. 2017 , 7, 12959	18
177	Microchip Circulation Drastically Accelerates Amyloid Aggregation of 1-42 β amyloid Peptide from <i>Felis catus</i> . 2017 , 8, 2558-2567	3
176	APP/A β structural diversity and Alzheimer's disease pathogenesis. 2017 , 110, 1-13	59
175	An A β -10-KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APP ^{swe} /PSEN1 ^{dE9} mice. 2017 , 1673, 72-77	8
174	Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease. 2017 , 60, 6664-6677	27
173	Coarse-grained and All-atom Simulations towards the Early and Late Steps of Amyloid Fibril Formation. 2017 , 57, 564-573	20
172	Prion-like disorders and Transmissible Spongiform Encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins. 2017 , 483, 1125-1136	20
171	Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. 2017 , 23, 5-22	239
170	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid- β 2 in Alzheimer's disease. 2017 , 140, 3301-3316	10
169	Alzheimer's Disease Pathogenesis: The Denied Access Model. 2017 , 07,	
168	Contribution of Nucleic Acids in the Pathogenesis of Alzheimer's Disease. 2017 , 129-162	
167	β Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. 2017 , 22,	62
166	Wild-Type, but Not Mutant N296H, Human Tau Restores A β -Mediated Inhibition of LTP in mice. 2017 , 11, 201	11
165	Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. 2018 , 26, 3133-3144	7
164	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. 2018 , 9, 1591-1606	13
163	Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region. 2018 , 26, 1035-1049	11

162	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. 2018 , 125, 591-613	13
161	Alzheimer's Disease, Oligomers, and Inflammation. 2018 , 62, 1261-1276	89
160	Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid- β -42 (pE3-A β) 2018 , 62, 1635-1649	7
159	Trace amounts of pyroglutaminated A β (3-42) enhance aggregation of A β (1-42) on neuronal membranes at physiological concentrations: FCS analysis of cell surface. 2018 , 1860, 1603-1608	4
158	A β truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. 2018 , 1864, 208-225	35
157	Early Alzheimer-type lesions in cognitively normal subjects. 2018 , 62, 34-44	24
156	Cu(II) binding to various forms of amyloid- β peptides. Are they friends or foes?. 2018 , 2018, 7-15	24
155	Amyloid- β and tau complexity - towards improved biomarkers and targeted therapies. 2018 , 14, 22-39	206
154	Organizing biochemistry in space and time using prion-like self-assembly. 2018 , 8, 16-24	11
153	3 .Neuropathologie und molekulare Mechanismen. 2018 , 35-122	0
152	Hippocampale synaptische Plastizität bei neurodegenerativen Erkrankungen: A β Tau und darüber hinaus. 2018 , 24, 203-212	
151	Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. 2018 , 23,	12
150	Mass spectrometry analysis of the diversity of A β peptides: difficulties and future perspectives for AD biomarker discovery. 2018 , 15, 773-775	10
149	Hippocampal synaptic plasticity in neurodegenerative diseases: A β tau and beyond. 2018 , 24, A133-A141	0
148	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. 2018 , 10, 107	48
147	Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of A β with Glutaminyl Cyclase-Catalyzed pGlu-A β Formation. 2018 , 66, 359-375	14
146	Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects. 2018 , 83, 1057-1067	15
145	Passive A β immunotherapy: Current Achievements and Future Perspectives. 2018 , 23,	29

144	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 302	6.1	18
143	Amyloid- β Drug Interactions from Computer Simulations and Cell-Based Assays. 2018 , 64, S659-S672		4
142	Neurochemical Aspects of Alzheimer's Disease and Movement Disturbances: A Theory of β Amyloid and β Protein. 2018 , 33, 535-540		5
141	Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models. <i>Journal of Genetics</i> , 2018 , 97, 783-793	1.2	4
140	Synergistic Effect on Neurodegeneration by N-Truncated A β and Pyroglutamate A β in a Mouse Model of Alzheimer's Disease. 2018 , 10, 64		10
139	AMPA Receptor Trafficking in Natural and Pathological Aging. <i>Frontiers in Molecular Neuroscience</i> , 2017 , 10, 446	6.1	35
138	N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid- β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease. 2018 , 14, 1302-1312		36
137	Peptides as Potential Therapeutics for Alzheimer's Disease. 2018 , 23,		32
136	Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-A β Formation. 2018 , 23,		8
135	Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. 2018 , 136, 589-605		19
134	Safety, tolerability and immunogenicity of an active anti-A β vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. 2018 , 10, 12		33
133	Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease. 2018 , 6, 3		45
132	Differential Modulation of the Aggregation of N-Terminal Truncated A β Using Cucurbiturils. 2018 , 24, 13647-13653		14
131	Effect of ferric citrate on amyloid-beta peptides behavior. 2018 , 109, e23224		6
130	Unveiling Brain A β Heterogeneity Through Targeted Proteomic Analysis. 2018 , 1779, 23-43		5
129	Alzheimer's disease in the omics era. 2018 , 59, 9-16		50
128	Effects of Prion Protein on A β 2 and Pyroglutamate-Modified A β 3-42 Oligomerization and Toxicity. 2019 , 56, 1957-1971		9
127	, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. 2019 , 13, 1177392819866412		31

126	Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design. 2019 , 62, 8011-8027	7
125	Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice. 2019 , 75, 105770	4
124	Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease. 2019 , 147, 104342	7
123	The molecular lifecycle of amyloid - Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. 2019 , 1867, 140257	20
122	Porphyromonas gingivalis Infection Induces Amyloid- β Accumulation in Monocytes/Macrophages. 2019 , 72, 479-494	39
121	The Development of Small Molecule Inhibitors of Glutaminyl Cyclase and Isoglutaminyl Cyclase for Alzheimer's Disease. 2019 , 4, 10591-10600	2
120	Intraneuronal Tau Misfolding Induced by Extracellular Amyloid- β Oligomers. 2019 , 71, 1125-1138	8
119	Effect of Post-Translational Modifications and Mutations on Amyloid- β Fibrils Dynamics at N-Terminus. 2019 , 117, 1524-1535	8
118	Tauopathy: A common mechanism for neurodegeneration and brain aging. 2019 , 178, 72-79	46
117	Seeding and Cross-Seeding Aggregations of A β and Its N-Terminal-Truncated Peptide A β 1-42. 2019 , 35, 2821-2831	8
116	A longitudinal model for tau aggregation in Alzheimer's disease based on structural connectivity. 2019 , 11492, 384-393	5
115	Molecular structure of an N-terminal phosphorylated β amyloid fibril. 2019 , 116, 11253-11258	29
114	High molecular weight amyloid β oligomers induce neurotoxicity plasma membrane damage. 2019 , 33, 9220-9234	36
113	Deuteron Solid-State NMR Relaxation Measurements Reveal Two Distinct Conformational Exchange Processes in the Disordered N-Terminal Domain of Amyloid- β Fibrils. 2019 , 20, 1680-1689	9
112	ApoE-fragment/A β heteromers in the brain of patients with Alzheimer's disease. 2019 , 9, 3989	14
111	Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid- β fibrils. 2019 , 294, 5840-5853	13
110	Ordered and Disordered Segments of Amyloid- β Drive Sequential Steps of the Toxic Pathway. 2019 , 10, 2498-2509	12
109	Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates. 2019 , 10, 7865-7874	8

108	QUINT: Workflow for Quantification and Spatial Analysis of Features in Histological Images From Rodent Brain. 2019 , 13, 75	13
107	Emerging roles of N- and C-terminally truncated A β species in Alzheimer's disease. 2019 , 23, 991-1004	24
106	Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis. 2019 , 187, 1173-1192	5
105	Deceleration of the neurodegenerative phenotype in pyroglutamate-A β accumulating transgenic mice by oral treatment with the A β oligomer eliminating compound RD2. 2019 , 124, 36-45	8
104	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?. 2020 , 57, 99-113	13
103	A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid- β toxicity. 2020 , 134, 104668	10
102	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease. 2020 , 131, 88-95	14
101	Inhibition and disaggregation of amyloid β protein fibrils through conjugated polymer-core thermoresponsive micelles. 2020 , 8, 10126-10135	10
100	Structural characteristics of oligomers formed by pyroglutamate-modified amyloid β peptides studied by solid-state NMR. 2020 , 22, 16887-16895	5
99	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. 2020 , 23, 1580-1588	23
98	Axonal Degeneration in AD: The Contribution of A β and Tau. 2020 , 12, 581767	9
97	The two faces of synaptic failure in App knock-in mice. 2020 , 12, 100	8
96	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. 2020 , 10,	10
95	Dynamics of Serine-8 Side-Chain in Amyloid- β Fibrils and Fluorenylmethyloxycarbonyl Serine Amino Acid, Investigated by Solid-State Deuteron NMR. 2020 , 124, 4723-4731	1
94	Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease. 2020 , 59, 2585-2591	6
93	The metastable states of proteins. 2020 , 29, 1559-1568	7
92	Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer's disease and related murine models. 2020 , 15, e0235543	5
91	Development of the clinical candidate PBD-C06, a humanized pGlu3-A β specific antibody against Alzheimer's disease with reduced complement activation. 2020 , 10, 3294	8

90	Intracerebral seeding of amyloid- β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with β -synuclein. 2020 , 112, 1-27		17
89	D-ribose and pathogenesis of Alzheimer's disease. 2020 , 47, 2289-2299		5
88	Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro. 2020 , 25,		23
87	Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models. <i>Brain Communications</i> , 2020 , 2, fcaa039	4.5	14
86	Recognition and Removal of Amyloid- β by a Heteromultivalent Macrocyclic Coassembly: A Potential Strategy for the Treatment of Alzheimer's Disease. 2021 , 33, e2006483		13
85	Inhibitory Effects of Isobavachalcone on Tau Protein Aggregation, Tau Phosphorylation, and Oligomeric Tau-Induced Apoptosis. 2021 , 12, 123-132		7
84	Mammalian-like type II glutaminyl cyclases in <i>Porphyromonas gingivalis</i> and other oral pathogenic bacteria as targets for treatment of periodontitis. 2021 , 296, 100263		3
83	Amyloid Beta. 2021 , 1-17		
82	Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease. 2021 , 17, 237-245		18
81	p53, A Victim of the Prion Fashion. 2021 , 13,		2
80	Mutual structural effects of unmodified and pyroglutamylated amyloid β peptides during aggregation. 2021 , 27, e3312		0
79	Aminopeptidase A contributes to biochemical, anatomical and cognitive defects in Alzheimer's disease (AD) mouse model and is increased at early stage in sporadic AD brain. 2021 , 141, 823-839		8
78	A New Monoclonal Antibody Shows Promise in Early Alzheimer's Disease. 2021 , 21, 13-14		
77	Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors. 2021 , 64, 6549-6565		2
76	A β 3 aggregates exhibit enhanced prion-like seeding activity in mice. 2021 , 9, 83		3
75	Alzheimer mutant speeds APP transport. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	1
74	A Unique Carboxylic-Acid Hydrogen-Bond Network (CAHBN) Confers Glutaminyl Cyclase Activity on M28 Family Enzymes. 2021 , 433, 166960		1
73	PEA β triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1

72	A glutaminy cyclase-catalyzed β synuclein modification identified in human synucleinopathies. 2021 , 142, 399-421	0
71	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. 2021 , 82, 541-560	3
70	Mild Microglial Responses in the Cortex and Perivascular Macrophage Infiltration in Subcortical White Matter in Dogs with Age-Related Dementia Modelling Prodromal Alzheimer's Disease. 2021 , 82, 575-592	0
69	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminy cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. 2021 , 13, 142	1
68	Longitudinal predictive modeling of tau progression along the structural connectome. 2021 , 237, 118126	1
67	Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease. 2021 , 1	7
66	Differential interaction with TREM2 modulates microglial uptake of modified A β species. 2021 , 69, 2917-2932	2
65	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1 63
64	Cross-Seeded Fibrillation Induced by Pyroglutamate-3 and Truncated A β Variants Leads to A β Structural Polymorphism Modulation and Elevated Toxicity. 2021 , 12, 3625-3637	2
63	Discovery of highly potent human glutaminy cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design. 2021 , 226, 113819	1
62	Interaction between A β and Tau in the Pathogenesis of Alzheimer's Disease. 2021 , 17, 2181-2192	10
61	Relationship Between Tau, β Amyloid and β Synuclein Pathologies. 2019 , 1184, 169-176	5
60	Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminy cyclase inhibitors. 2021 , 170, 415-423	4
59	Structural and dynamical mechanisms of a naturally occurring variant of the human prion protein in preventing prion conversion. 2020 , 29, 108710	1
58	A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid- β toxicity.	1
57	Effector function of anti-pyroglutamate-3 A β antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. 2020 , 12, 12	15
56	Neurofibrillary tangles and the deposition of a beta amyloid peptide with a novel N-terminal epitope in the brains of wild Tsushima leopard cats. 2012 , 7, e46452	16
55	Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. 2020 , 21, 148-166	7

54	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. 2013 , 11, 491-8		41
53	BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer's disease. 2016 , 11, 447-53		18
52	The physical dimensions of amyloid aggregates control their infective potential as prion particles. 2017 , 6,		19
51	Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers. 2021 , 12, 619388		0
50	Pick's Disease: The Evolution of Theory and Knowledge in Neurodegenerative Tauopathies. 2015 , 127-138		
49	A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate A β peptides.		
48	Amyloid Beta. 2019 , 235-251		1
47	Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches. 2020 , 19, 174-183		2
46	Combination of the Glutaminy Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A β Pathology in Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
45	Neurotoxicity of different amyloid beta subspecies in mice and their interaction with isoflurane anaesthesia. 2020 , 15, e0242989		2
44	Repurposing FDA-Approved Compounds for the Discovery of Glutaminy Cyclase Inhibitors as Drugs Against Alzheimer's Disease. 2021 , 10, 877-881		1
43	Tau and neuron aging. 2013 , 4, 23-8		8
42	Therapies for human prion diseases. 2013 , 2, 176-86		22
41	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model. <i>Current Alzheimer Research</i> , 2016 , 13, 663-77	3	4
40	Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation. <i>Nature Communications</i> , 2021 , 12, 6565	17.4	4
39	O-Glycosylation Induces Amyloid- β To Form New Fibril Polymorphs Vulnerable for Degradation. <i>Journal of the American Chemical Society</i> , 2021 , 143, 20216-20223	16.4	5
38	Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. <i>Journal of Neurochemistry</i> , 2021 ,	6	2
37	An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: pyroglutamate amyloid beta.. <i>Brain Communications</i> , 2022 , 4, fcac022	4.5	0

36	Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease.. <i>Frontiers in Molecular Neuroscience</i> , 2021 , 14, 821002	6.1	1
35	Neddylation-dependent protein degradation is a nexus between synaptic insulin resistance, neuroinflammation and Alzheimer's disease.. <i>Translational Neurodegeneration</i> , 2022 , 11, 2	10.3	2
34	Gut microbiota-driven brain A β amyloidosis in mice requires microglia. <i>Journal of Experimental Medicine</i> , 2022 , 219,	16.6	7
33	Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models. <i>Journal of Genetics</i> , 2018 , 97, 783-793	1.2	1
32	Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	3
31	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
30	Pyroglutamate A β cascade as drug target in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	6
29	Data_Sheet_1.ZIP. 2019 ,		
28	Table_1.DOCX. 2019 ,		
27	Data_Sheet_1.pdf. 2018 ,		
26	N-terminally truncated A β -x proteoforms and their relevance for Alzheimer's pathophysiology. <i>Translational Neurodegeneration</i> , 2022 , 11,	10.3	0
25	Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. <i>Pharmacological Reviews</i> , 2022 , 74, 600-629	22.5	5
24	Prion diseases. 2023 , 361-378		
23	Immunohistochemical Demonstration of the pGlu79 β -Synuclein Fragment in Alzheimer's Disease and Its Tg2576 Mouse Model. <i>Biomolecules</i> , 2022 , 12, 1006	5.9	0
22	Alpha synuclein processing by MMP-3 β implications for synucleinopathies. <i>Behavioural Brain Research</i> , 2022 , 114020	3.4	
21	Pivotal role of nitrogen heterocycles in Alzheimer's disease drug discovery. <i>Drug Discovery Today</i> , 2022 ,	8.8	1
20	Oligomeropathies, inflammation and prion protein binding. 16,		1
19	2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRP β Checkpoint.		

- 18 Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases. **2022**, 931, 175178
- 17 Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability. 1
- 16 Characterization of microtubule-associated protein tau isoforms and Alzheimer's disease-like pathology in normal sheep (*Ovis aries*): relevance to their potential as a model of Alzheimer's disease. **2022**, 79, 0
- 15 Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents. **2022**, 244, 114837 0
- 14 The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. **2023**, 131, 106301 3
- 13 Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells. **2022**, 2022, 1-15 0
- 12 Insights into the Mixture of A β 4 and A β 2 Peptides from Atomistic Simulations. **2022**, 126, 10689-10696 0
- 11 Putative Structures of Membrane-Embedded Amyloid β Oligomers. 1
- 10 A novel human tau knock-in mouse model reveals interaction of A β and human tau under progressing cerebral amyloidosis in 5xFAD mice. **2023**, 15, 0
- 9 Functions of glutaminyl cyclase and its isoform in diseases. **2023**, 4, 1 0
- 8 Localization, induction, and cellular effects of tau phosphorylated at threonine 217 1. 0
- 7 Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3 β . **2023**, 248, 115089 0
- 6 How Single Site Mutations Can Help Understanding Structure Formation of Amyloid β 40. 2200489 0
- 5 Cellular response to β amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics. **2023**, 6, 3-9 0
- 4 A comprehensive characterization of hippocampal feature ensemble serves as individualized brain signature for Alzheimer's disease: deep learning analysis in 3238 participants worldwide. 0
- 3 Natural essential oils derived from herbal medicines: A promising therapy strategy for treating cognitive impairment. 15, 0
- 2 Brain Network Homeostasis and Plasticity of Salidroside for Achieving Neuroprotection and Treating Psychiatric Sequelae Stemming from Stress. 0
- 1 Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation. **2023**, 18, 0

